Merck & Co., Inc.MRK

Healthcare
Neutral

ASignal's systematic analysis rates MRK as Neutral. Merck & Co., Inc. has a market cap of $321.57B, a P/E of 36.47, a 13.6% net margin, and 4.9% year-over-year revenue growth.

Reflects the latest available analysis · analyzed Aug 1, 2026

The case on MRK

Bull vs bear, surfaced by ASignal's framework agents from public market data. The precise verdict: ASignal Rank, confidence, and price targets - is in the app.

Bull case
  • Positive MACD histogram indicating strengthening upward momentum
  • Price above SMA20 and SMA50, suggesting uptrend
  • Strong gross margin of 76.73% indicating pricing power
  • Return on equity of 18.94% above 15% threshold for strong capital efficiency
  • Free cash flow of $14.05B supports financial stability
VS
Bear case
  • Debt-to-equity ratio of 1.07x above 1.0 threshold, indicating high leverage
  • High PEG ratio of 12.07x suggesting overvaluation relative to growth
  • P/E of 36.47x significantly above market average
  • Quick ratio of 0.70x below 1.0, indicating potential liquidity concerns
  • Dividend yield of 262.00% is unsustainable and likely erroneous or distorting

Key facts

Sector
Healthcare
Market cap
$321.57B
P/E ratio
36.47
Gross margin
76.7%
Net margin
13.6%
Rev growth YoY
4.9%
Price (Aug 1, 2026)
$130.2

Peers

Clustered with MRK by analysis-profile similarity.

Subscriber-only

See the full verdict on MRK

ASignal Rank (1-4), confidence score, Buffett / Ackman / Dalio grades, price targets, and the full reasoning behind the call.

How ASignal analyzes MRK

Most investors never get a second opinion, let alone several. ASignal runs MRK past a panel of specialized investor-framework agents, each calibrated on a distinct school of investing: Warren Buffett's value discipline, Bill Ackman's activist lens, and Ray Dalio's macro view. They don't just score in isolation, they argue: a dedicated Challenger agent pushes back on every conclusion until the panel settles on a reasoned consensus, weighing fundamentals, macro conditions, market sentiment, and price action together. The kind of cross-examined read that takes a research desk hours, ASignal delivers in under two minutes, refreshed every cycle.

The signal direction and the bull and bear case above are free. The precise read, ASignal Rank, framework grades, price targets, and full reasoning, stays with subscribers.

Merck & Co., Inc. (MRK) Stock Analysis - ASignal rates it Neutral